ѻý

MedpageToday
ASCO > Lung Cancer

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or Combined With Oleclumab or Monalizumab in Unresectable Stage III NSCLC

<ѻý class="mpt-content-deck">– An ASCO Reading Room selection
Roy S. Herbst, MD, PhD; Margarita Majem, MD, PhD; Fabrice Barlesi, MD, PhD; Enric Carcereny, MD; Quincy Chu, MD; Isabelle Monnet, MD, PhD; Alfredo Sanchez-Hernandez , MD; Shaker Dakhil, MD; D. Ross Camidge, MD, PhD; Leanne Winzer, MSc; Yee Soo-Hoo, MPH; Zachary A. Cooper, PhD; Rakesh Kumar, MD, PhD; John Bothos, PhD; Charu Aggarwal, MD, MPH; and Alex Martinez-Marti, MD
Journal of Clinical Oncology

This Reading Room is a collaboration between ѻý® and:

Medpage Today
Below is the abstract of the article.
Read the full article PDF by clicking here
or on the link below.

Purpose

Durvalumab significantly improves overall survival for patients with unresectable stage III non–small-cell lung cancer and no progression after concurrent chemoradiotherapy (cCRT). Building upon that standard of care, COAST is a phase II study of durvalumab alone or combined with the anti-CD73 monoclonal antibody oleclumab or anti-NKG2A monoclonal antibody monalizumab as consolidation therapy in this setting.

Methods

Patients with unresectable stage III non–small-cell lung cancer, Eastern Cooperative Oncology Group performance status 0/1, and no progression after cCRT were randomly assigned 1:1:1, ≤ 42 days post-cCRT, to durvalumab alone or combined with oleclumab or monalizumab for up to 12 months, stratified by histology. The primary end point was investigator-assessed confirmed objective response rate (ORR; RECIST v1.1).

Results

Between January 2019 and July 2020, 189 patients were randomly assigned. At this interim analysis (data cutoff, May 17, 2021), median follow-up was 11.5 months (range, 0.4-23.4 months; all patients). Confirmed ORR was numerically higher with durvalumab plus oleclumab (30.0%; 95% CI, 18.8 to 43.2) and durvalumab plus monalizumab (35.5%; 95% CI, 23.7 to 48.7) versus durvalumab (17.9%; 95% CI, 9.6 to 29.2). Progression-free survival (PFS) was prolonged with both combinations versus durvalumab (plus oleclumab: hazard ratio, 0.44; 95% CI, 0.26 to 0.75; and plus monalizumab: hazard ratio, 0.42; 95% CI, 0.24 to 0.72), with higher 12-month PFS rates (plus oleclumab: 62.6% [95% CI, 48.1 to 74.2] and plus monalizumab: 72.7% [95% CI, 58.8 to 82.6] v durvalumab alone: 33.9% [95% CI, 21.2 to 47.1]). All-cause grade ≥ 3 treatment-emergent adverse events occurred in 40.7%, 27.9%, and 39.4% with durvalumab plus oleclumab, durvalumab plus monalizumab, and durvalumab, respectively.

Conclusion

Both combinations increased ORR and prolonged PFS versus durvalumab alone. Safety was similar across arms with no new or significant safety signals identified with either combination. These data support their further evaluation in a phase III trial.

Read an interview about the study here.

Read the full article

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or Combined With Oleclumab or Monalizumab in Unresectable Stage III NSCLC

Primary Source

Journal of Clinical Oncology

Source Reference:

ASCO Publications Corner

ASCO Publications Corner